The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) held its fifth meeting November 26-29, 2012, at which the PRAC started a review of four medicines that are nationally authorized in European Union member states.
The Committee also evaluated evidence for new safety signals from EU reporting systems, assessed updated risk management plans for certain medicines and discussed a number of periodic safety update reports.
The four products to be evaluated are:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze